Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Carotid Endarterectomy Yields Better Short-Term Results Compared to Stenting

By HospiMedica International staff writers
Posted on 21 Jan 2009
A new study has found that both symptomatic and asymptomatic carotid artery stenting (CAS) patients had significantly higher 30-days post-procedure incidence of death, stroke, or myocardial infarction (MI), when compared to Carotid Endarterectomy (CEA) patients.

Researchers at the Veterans Affair Medical Center (VAMC, Washington, DC, USA), Washington University (St. More...
Louis, MI, USA), New England Research Institutes (Watertown, MA, USA), and other members of the Outcomes Committee of the Society for Vascular Surgery Vascular Registry (SVS-VR) reviewed data on 6,403 procedures performed by 287 providers at 56 centers across the United States. An additional 1,450 CAS patients and 1,368 CEA patients with 30-day outcomes were also included in the study. The primary outcomes were combined death, stroke, and myocardial infarction (MI).

The study results showed that after risk-adjustment for age, history of stroke, diabetes, and other factors found to be significant confounders; logistic regression analysis suggested better outcomes following CEA. For CAS, death, stroke, or MI at 30 days was 7.13% for symptomatic patients and 4.60% for asymptomatic patients; for CEA, death, stroke, or MI at 30 days was 3.75% in symptomatic patients and 1.97% in asymptomatic patients. When CAS and CEA were compared in the treatment of atherosclerotic disease only, the difference in outcomes between the two procedures was more pronounced, with death, stroke, or MI at 6.42% after CAS compared to 2.62% following CEA. The study was published in the January 2009 issue of the Journal of Vascular Surgery.

"The majority of patients were treated because of atherosclerotic disease,” said senior author Professor Anton Sidawy, M.D., MPH, chief of vascular surgery at VAMC. "In general, there was a greater proportion of CAS patients with preprocedure lateralizing neurological symptoms, as well as higher prevalence of cardiac comorbidities compared with CEA patients.”

"This initial report from the Vascular Registry provides proof of concept that a specialty society-based vascular registry can succeed in meeting regulatory and scientific goals,” said Professor Gregorio Sicard, M.D., chairman of the SVS Outcomes Committee and chief of vascular surgery at Washington University. "With continued enrollment and follow-up, analysis of SVS Vascular Registry will supplement randomized trials by providing real-world comparisons of CAS and CEA with sufficient numbers to serve as an outcome assessment tool of important patient subsets and across the spectrum of peripheral vascular procedures.”

The SVS Vascular Registry for Carotid Procedures currently has 77 participating clinical facilities and over 9,700 patients. The SVS-VR provides semi-annual institutional benchmarking reports to participating facilities on outcomes by procedure. The New England Research Institutes serves as the independent data coordinating center, maintaining the database, and performing statistical analysis. The SVS designed the Vascular Registry with potential for expansion to procedures involving other vascular beds.

Related Links:
Veterans Affair Medical Center
Washington University
New England Research Institutes


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.